Skip to main content
Equibles
EVFM logo

EVFM · Evofem Biosciences, Inc.

Track EVFM — free

Use EVFM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EVFM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.50 At close · Aug 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.06M
Shares
132.53M
Volume · Aug 11 58.6K Avg daily vol (3M) —

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$57.50 Open$48.75 Day$48.13–59.88 52W close$35.88–1,663.13 Avg vol 30d290K Short int390 · 0.0% float · 1.0d Short vol11% Last earningsAug 4, 2022 DataJan 2020–Aug 2022 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −90%
below
Price vs 50-day avg −37%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 1%
near low
Momentum
relative strength
Very Weak
1-month return −57%
trailing
6-month return −94%
trailing
YTD return −92%
this year
Relative strength −90%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $91 › 200d $548 — 200d above 50d
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -96.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 4-yr low, contrarian setup
Fundamentals
Strong
Revenue growth +104%
Y/Y
EPS growth +100%
Y/Y
Free cash flow $-2.0M
Balance sheet $27.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 229%
annualized · 1-yr
Max drawdown −98%
past year
ATR 34.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−90% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $91 › 200d $548 — 200d above 50d
Institutional flow Accumulating
+1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -96.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $36 Now $58 · 1% Range high $1,663
vs 200-day avg -90% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EVFM
Evofem Biosciences, Inc.
this stock
$1.06M — +104.2% — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1
% held
0.0%
Net QoQ
+1 sh
Top holder
BESSEMER GROUP INC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
390
Days to cover
1.0d
Change
-10.9K sh
View
Short Volume
Short vol %
11%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
938
Value
$0
As of
Apr 2, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 8, 2022
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$20.2M
Net income (FY)
$391.0K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 23, 2026
This year
12
View
Exempt Offerings
Offering
$925.0K
Filed
Jul 2, 2025
View
Earnings & Events
Webcasts
Last webcast
Aug 4, 2022
View
Investor Relations
Latest news
Evofem Biosciences Adds Additiona…
Published
Sep 23, 2026
View

Performance

5D 20D 120D MTD YTD
EVFM -48.8% -57.0% -93.6% -37.0% -91.8%
SPY +1.4% +11.1% -3.9% +1.9% -11.6%
vs SPY -50.2% -68.1% -89.7% -38.9% -80.3%
Key facts CIK 1618835 CUSIP 30048L302 Visit website Investor relations